|
October 1, 2011
By:
William Looney
Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant.
|
October 1, 2011
30 Years of Pharma: Perspective in Numbers
|
December 1, 2007
By:
Sarah Houlton
One of industry's main complaints is that delaying the introduction of new medicines is a particularly simple way of saving money
|
December 1, 2007
By:
Joanna Breitstein
Science is the lifeblood of pharma, of course. But these days, science isn't just what you produce in your own labs. It's what you can license, buy, partner on, or gain through acquisition. Which means that, increasingly, deals are the lifeblood of pharma.
|
November 1, 2007
By:
Jill Wechsler
FDAAA aims to restore public trust in drug safety regulation but may curb investment in R&D
|
November 1, 2007
By:
Patrick Clinton
A hospital safety expert says it's now possible to completely eliminate certain adverse events. Pharma can't claim the same yet, but is it time for us to start imagining a time when we can "benchmark perfection"?
|
|
November 1, 2007
By:
Mike Maguire
In this age of new media, social networking, blogs, and cyber-clutter, it's easy to forget the appeal of the real—of things that you can hold in your hand and engage with physically. But make no mistake, despite all of the high-tech tools available to us, advertising still relies on evoking an emotional response by tickling the human senses.
|
|
November 1, 2007
By:
Tammy Prouty
Most people exhibit characteristics of both visual and verbal learning styles and learn most effectively when information is presented through a combination of the two
|
November 1, 2007
By:
Sander A. Flaum
We have nothing to fear but the fear of change (with apologies to the wise Franklin D. Roosevelt). But we must get over that if we hope to make a real difference.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
